Pediatric Cancer

The Pediatric MATCH Study: Actionable Targets Found in 25% of Young Patients with Cancer

Wayne Kuznar

August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO 2019 Highlights - Pediatric Cancer

Chicago, IL—Approximately 25% of children, adolescents, and young adults with advanced cancer were eligible for a targeted therapy after genotyping of their tumors in the Pediatric Molecular Analysis for Therapy Choice (MATCH) clinical trial. That rate is more than double the 10% that researchers had projected. [ Read More ]